Recent #JIPO research article by Ahmed et al. tests the combination of #spartalizumab with #lacnotuzumab in patients with advanced malignancies doi.org/10.36401/JIPO-… Jibran Ahmed #oncology #clinicaltrials

Research article by Muhammed et al. examines the "Factors That Influence the Need to Start Adaptive Radiotherapy" loom.ly/saGLMZo #radiotherapy #oncology

It's almost time for #POF2024! Join us in Cincinnati for the Precision Oncology Forum on March 2nd, and learn about the latest advances in the field. Register today: tinyurl.com/28jut4be #JIPO #immunotherapy #precisiononcology Innovative Healthcare Institute Innovations Journals Innovative Oncology Network

Be the first to know about new issues, community events, and industry developments in #precisiononcology when you subscribe to #JIPO! #oncology #immunotherapy tinyurl.com/2jp49b7f

🚨Call for Peer Reviewers🚨 Peer Reviewing is an amazing way of sharing knowledge and contributing for higher levels of evidence! Give it a try and apply for #JIPO! JIPO Editors Aung Naing Camila Braganca Xavier Abdulrazzak Zarifa, MD Mohamed A Gouda

#JIPO review investigates prescence of common oral toxicities & their reactions w #ICIs, by Srivastava et al. Article: doi.org/10.36401/JIPO-… Interview: loom.ly/kz_6Spc #immunotherapy #inhibitors Aysun Ş. Yıkılmaz

BREAKING: U.S. FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for Unresectable or Metastatic HER2+ Solid Tumors #oncology #medtwitter onclive.com/view/fda-grant…

Out on The Lancet Oncology : ENZA P Combining enzalutamide with [177Lu]Lu-PSMA-617 ✅Significantly extends median PSA PFS in metastatic castration-resistant #ProstateCancer 🆚enzalutamide alone. 💥Promising avenue for enhanced treatment💥 Louise Emmett Shalini Subramaniam DrAndrewWeickhardt

#exercise before, during & after cancer treatment has been shown to improve outcomes 🚶🏃🏼‍♀️🏈⚽️🏌️⛷️🏊🏻‍♀️🚣‍♂️ It should be a regular and integrated part of #Cancer care Aktiv mot kreft Ung Kreft Kreftforskning_ous Oslounivsykehus OncoAlert

Antibody-Drug Conjugates: Advancing from magic bullet to biological missile. bit.ly/3QmlaID

I’ve told you guys before😉 You can trust-uzumab deruxtecan!

The 1st-in-human phase 1 study on arginase inhibitor INCB001158 is out on BMJ Oncology 💉💉 Led by my great mentor Aung Naing Tested a strong preclinical hypothesis 🤓🤓 ☑️A total of 107 patients ☑️Monotherapy or with pembro- ➕Tolerable with fatigue and GI adverse events

A very insightful analysis on the landscape of Drug Development in Latin America by Mirella Nardo, MD, Camila Braganca Xavier et al. JIPO Editors

Interesting strategy targeting TP53: 1. Induced proximity approach to selectively kill TP53 mutant cells. 2. A small molecule targeting Y220C mutant of p53 concentrates a PLK1 inhibitor inducing cell death.

🚨It's Friday and we have another FDA approval ! 👉FDA Approves First Gene Therapy to Treat Adults with Metastatic Synovial Sarcoma 👉Afamitresgene autoleucel is also the first FDA-approved T cell receptor (TCR) gene therapy. 👉The product is an autologous T cell immunotherapy

Review the #JIPO research by Sanford et al. assessing the gut microbiome of patients undergoing treatment for rectal cancer doi.org/10.36401/JIPO-… #colorectalcancer Dr. Nina Niu Sanford

News—BRAF–MEK Inhibitor Combo OK’d in Europe for NSCLC. bit.ly/4g7SoH1?

Interesting discussion about the possibilities/challenges associated to PROTAC/Molecular Glues development @ICR_RM_DDU! Thank you Adam Sharp, udaibanerji, Anna Minchom for the great insights!

Congrats to Victor Ambros and Gary Ruvkun for being awarded the 2024 Nobel Prize in Physiology or Medicine "for the discovery of microRNA and its role in post-transcriptional gene regulation". Check out this Nature Collection that celebrates this topic: go.nature.com/3NjioSs